Clinical Trial Update: Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating inhaled therapy for idiopathic pulmonary fibrosis has completed, sponsored by GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Snippet

Sponsor: GlaxoSmithKline | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED